Advertisement
"The major bottleneck that limits the translation of readily availablegenomic information into the development of next generation diagnostics,vaccines and therapeutics, is the continued lack of effective antigen andbiomarker discovery tools," said Dr. Xiaowu Liang, CEO of ADI. "We aregrateful that the SBIR program continues to fund ADI and our UCI collaboratorsin the further development of this exciting new technology platform that trulyrevolutionizes the screening and detection of disease markers."
Advertisement
"The focus of this grant is to commercialize some of the broadapplications of the platform technology that were developed during previousfunding phases. The establishment of a Good Manufactuing Practices (GMP)facility, and a Clinical Research Lab will enable us to offer diagnosticproducts and services to physicians, point of care facilities, developers ofnovel vaccines, and pharmaceutical researchers," added Dr. Huw Davies, thePrincipal Investigator on the SBIR grant. "By using our novel protein arraysystems and statistical algorithms, we can rapidly discover antigen sets thatwill provide serological tests that discriminate between different infections,or even between different stages of the same infection."
About Antigen Discovery Inc.
Antigen Discovery Inc. (formerly ImmPORT Therapeutics Inc.) is a privatelyheld biotech company with innovative technologies that offer unprecedentedadvantages for the rapid development of safer and more effective vaccines anddiagnostic products. The Company's high throughput proteome microarray chipfabrication and screening platform provides an order of magnitude ofimprovement over current antigen/biomarker discovery technologies. Thetechnology also has potential applications in the identification of markersfor autoimmune disease and cancer.
SOURCE Antigen Discovery Inc.
